Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Unknown × INDUSTRY × MEK inhibitor I × Clear all

Phase

Status

Unknown 1 Completed 1

Sponsor Class

OTHER 1 INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Interventions

Injections 47 Cisplatin 46 Paclitaxel 45 Carboplatin 39 Gemcitabine 34 Docetaxel 34 Drug Therapy 30 Capecitabine 30 pembrolizumab 27 Bevacizumab 24 icotinib 21 anlotinib 21 Fluorouracil 20 Cyclophosphamide 20 fludarabine 16 Pemetrexed 16 Oxaliplatin 16 Irinotecan 16 Cetuximab 14 apatinib 12 Temozolomide 12 Nivolumab 12 Leucovorin 12 Fulvestrant 11 Doxorubicin 11 tesetaxel 10 camrelizumab 10 Trastuzumab 9 SHR-1701 9 Rituximab 9

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02968485 2019-01-15

Phase I Study of SHR7390 in Patients With Advanced Solid Tumors

Jiangsu HengRui Medicine Co., Ltd.

Phase 1 Unknown

Other solid neoplasm

Solid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon ⚡